Syntalpharmasp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2015-04-03
Share capital
300 000,00 PLN
Activity description

Syntalpharma provides custom synthesis, including multi-step synthesis of intermediates for APIs, along with GMP documentation and cleanroom facilities. The company scales processes from milligrams to many kilograms and offers contract manufacturing under cGMP rules.

Registered address
ul. Łabędzka 59, 44-121 Gliwice, Poland
Website
syntalpharma.com
Phone
Electronic delivery address
AE:PL-92026-67085-BVJUF-24

Financials

Financial statements filed on time (last 5 years).

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 1.04mMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD 298.76kMedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 701.47kMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 1.04mMedianUSD 883.09kAverageUSD 31.39m

Industry

Bank accounts

Registered as a VAT taxpayer on 2015-04-09.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

4 public aid cases recorded, with a total value of $139.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$34
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$46
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$40

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Simon John Isherwood – Vice President of the Management Board
Zbigniew Jezierski – President of the Management Board

Manner of representation

Each member of the management board is authorised to represent the company independently.

Ownership

OwnerSharesShare valueStake
Simon John Isherwood
2,700$27,012.4333.3333%
Urszula Jezierska (70)
2,700$27,012.4333.3333%
Krzysztof Zemlak (58)
600$27,012.4333.3333%

Beneficial owners

Person

Competitors

Name
Elanda Pharmasp. z o.o.
Actifarmsp. z o.o.
Labor Przedsiębiorstwo Farmaceutyczno - Chemicznesp. z o.o.
Symbio-Labsp. z o.o.
F1 PharmaS.A.
Pexon Polandsp. z o.o.

FAQ

Last updated: 2026-05-07